Short answer
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
MADRIGAL PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Investor-relevant figures and management commentary contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Rezdiffra Q3 net sales $431.3M, up 50% year over year, driving Madrigal’s first quarterly profitability
- Net income $55.4M, or $1.83 diluted EPS, versus $114.2M net loss in the prior-year quarter
- Year-to-date Rezdiffra sales $1.1B, reaching blockbuster status with more than 55,850 patients treated
- Cash, restricted cash and marketable securities $961.8M as of September 30, 2026, supporting commercialization and clinical investment
- Planned MAESTRO-CSPH Phase 3 trial targets more than 2,000 F4c patients, expanding Rezdiffra’s potential beyond F2-F3 MASH
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MADRIGAL PHARMACEUTICALS, INC. 8-K filings
Get the next MDGL 8-K as it lands
Follow MDGL for push alerts, or ask the research agent what this filing means.